IMAGE

Figure 1—figure supplement 3.

ID: ZDB-IMAGE-210218-28
Publication: Fazio et al., 2021 - SATB2 induction of a neural crest mesenchyme-like program drives melanoma invasion and drug resistance
All Figures: Figures for Fazio et al., 2021

Image

Figure Caption

Figure 1—figure supplement 3. SATB2 is not sufficient and unlikley necessary for melanoma initiation in zebrafish.

(A) Kaplan-Meier survival curves showing that MCR:SATB2 acceleration is dependent on BRAF^V600E and p53^-/-. Plotted: MCR:EGFP (n = 44) and MCR:SATB2 (n = 98) into Tg(mitfa:BRAF^V600E); p53^-/-; mitfa^-/-, compared to MCR:SATB2 into BRAF^-/-; p53^-/- (n = 44) and MCR:SATB2 into BRAF^+/+; p53^+/+ (n = 49). Log-rank (Mantel-Cox) test p values are shown. (B) T7E1 mutagenesis assay at the CRISPR target site in the satb2 gene. The assay was performed on genomic DNA from 2 dpf embryos injected at the one-cell stage with Cas9 mRNA and either a control gRNA (left) or a gRNA against satb2 (right). Cleavage bands (arrowheads, expected sizes 167 and 303 bp) indicate efficient mutagenesis at the target site. (C) Kaplan-Meier survival curves for p53 CRISPR (n-46), satb2 CRISPR-1 (n = 74), satb2 CRISPR-2 (n = 76) injected into [Tg(mitfa:BRAF^V600E); p53^-/-; mitfa^-/-] suggest satb2 to likely be dispensable for melanoma initiation. Log-rank (Mantel-Cox) test, NS; not significant, ****p<0.0001. (D) Kaplan-Meier survival curves for MCR:SATB2 (n = 98), MCR:SATB1 (n = 107), and MCR:EGFP (n = 44) into Tg(mitfa:BRAF^V600E); p53^-/-; mitfa^-/- showing that unlike SATB2, closely related gene SATB1 does not accelerate melanoma onset. Log-rank (Mantel-Cox) test, NS; not significant, ****p<0.0001.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Elife